Gail Kirby
Nurse Practitioner · Greer, SCNPI 1760460869
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Novartis at 27.4% of the total. Reporting peaked in 2023 at $7,382 and has fallen 74.2% since, to $1,904 in 2025. Among nurse practitioner clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 318 payments — averaging $56.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$5K
- Amgen$4K
- AstraZeneca$3K
- Bayer$766
- OPKO Pharmaceuticals, LLC$638
- Akebia Therapeutics Inc$586
- plus $3K from 19 others
What the payments were for
- Consulting fees$4,87527%
- Speaking & faculty fees$2,30013%
- Travel & lodging$2,61315%
- Food & beverage$7,41241%
- Education$7804%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 17 | $4,934 |
| Amgen(2 entities) | 62 | $4,494 |
| AstraZeneca(2 entities) | 50 | $3,445 |
| Bayer | 33 | $766 |
| OPKO Pharmaceuticals, LLC | 16 | $638 |
| Akebia Therapeutics Inc | 19 | $586 |
| Travere Therapeutics, Inc. | 18 | $524 |
| Calliditas Therapeutics US Inc. | 15 | $483 |
| Otsuka America Pharmaceutical, Inc. | 20 | $349 |
| Novo Nordisk | 6 | $257 |
| Ardelyx, Inc. | 6 | $235 |
| Mallinckrodt Hospital Products Inc. | 6 | $206 |
| Boehringer Ingelheim | 6 | $206 |
| Vifor Pharma, Inc. | 12 | $203 |
| GSK | 10 | $175 |
| Lilly USA, LLC | 8 | $166 |
| Nxstage Medical, Inc. | 1 | $80 |
| Fresenius USA Marketing, Inc. | 4 | $69 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $37 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Aurinia Pharma U.S., Inc. | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Athena Bioscience, LLC | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,980 in reported general payments places this provider in the 95th percentile of 1,346 nurse practitioner providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 137 | $158,831 |
| JardianceEmpagliflozin | 71 | $94,199 |
| VelphoroSucroferric Oxyhydroxide | 16 | $92,905 |
| KerendiaFinerenone | 33 | $38,779 |
| VeltassaPatiromer Calcium Sorbitex | 24 | $30,094 |
| LokelmaSodium Zirconium Cyclosilicate | 40 | $27,746 |
| RayaldeeCalcifediol | 14 | $16,616 |
| Sevelamer Carbonate | 44 | $8,609 |
| Calcium Acetate | 72 | $8,327 |
| Torsemide | 153 | $4,020 |
| Isosorbide Dinitrate | 12 | $1,908 |
| Amlodipine Besylate | 197 | $1,116 |
| Losartan Potassium | 108 | $1,035 |
| Pantoprazole Sodium | 41 | $1,023 |
| Bumetanide | 20 | $994 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $3,445 | $186,577177 claims |
| Boehringer IngelheimJardiance | $206 | $94,19971 claims |
| Fresenius USA Marketing, Inc.Velphoro | $69 | $92,90516 claims |
| BayerKerendia | $766 | $38,77933 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $638 | $16,61614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,346 nurse practitioner providers in South Carolina.
Other nurse practitioner in Greer
- David WiltGreenville$90K
- Whitney ReedCharleston$54K
- Mary JohnsonCharleston$34K
- Amanda HareCharleston$30K
- Kellie McLainCharleston$28K
- Colleen BoydSummerville$21K
- Mae BurtonGreenville$21K
- Melissa BramanteColumbia$19K
- Alissa StrojnyMyrtle Beach$18K
- Stacey Bulfinch IdicaAiken$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.